 | In a letter to the Institute for Clinical and Economic Review (ICER), the Partnership to Improve Patient Care (PIPC) offered comments on ICER's draft evidence report for Hypertrophic Cardiomyopathy (HCM) treatments. |
The letter criticizes ICER's assessment of mayacamten, the HCM treatment at the focal point of this report, for being conducted prior the completion of ongoing studies into the drug's long-tern effectiveness. PIPC also took issue with ICER for its reliance on the discriminatory quality-adjusted-life-years (QALY) metric, as well as refusing to incorporate key outcomes requested by patients and clinicians in constructing this model.
"ICER’s model underestimates the wider burden of HCM and does not appear to have the granularity required to adequately evaluate interventions for this population," wrote PIPC Chair Tony Coelho. "We would encourage ICER to listen to the feedback it received from patient and clinician stakeholders and to broaden its model beyond just NYHA classes."
"ICER’s model underestimates the wider burden of HCM and does not appear to have the granularity required to adequately evaluate interventions for this population," wrote PIPC Chair Tony Coelho. "We would encourage ICER to listen to the feedback it received from patient and clinician stakeholders and to broaden its model beyond just NYHA classes."
| icer__hcm_final_for_submission.pdf |
